SCPHscPharmaceuticals Inc.

Nasdaq scpharmaceuticals.com


$ 4.76 $ -0.08 (-1.55 %)    

Friday, 17-May-2024 15:59:53 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 4.75
$ 4.80
$ 0.00 x 0
$ 0.00 x 0
$ 4.70 - $ 4.84
$ 4.01 - $ 11.75
237,059
na
185.02M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-22-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-22-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-11-2021 06-30-2021 10-Q
13 05-12-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 03-21-2019 12-31-2018 10-K
23 11-13-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-07-2018 03-31-2018 10-Q
26 03-21-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

 scpharmaceuticals-q1-2024-gaap-eps-036-beats-044-estimate-sales-610m-beat-598m-estimate

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0...

 scpharmaceuticals-enrolls-first-participant-in-pivotal-pharmacokinetic-study-of-furoscix-auto-injector-injection

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2...

 hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

 scpharmaceuticals-q4-2023-gaap-eps-035-beats-042-estimate-sales-6096m-beat-5525m-estimate

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0...

 earnings-scheduled-for-march-13-2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

 scpharmaceuticals-q3-eps-041-misses-036-estimate-sales-380m-beat-339m-estimate

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $...

 earnings-scheduled-for-november-8-2023

Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.

 scpharmaceuticals-announces-feedback-from-two-fda-meetings-related-to-the-development-of-an-80mg1ml-auto-injector

Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system ...

 craig-hallum-initiates-coverage-on-scpharmaceuticals-with-buy-rating-announces-price-target-of-20

Craig-Hallum analyst Chase Knickerbocker initiates coverage on scPharmaceuticals (NASDAQ:SCPH) with a Buy rating and announc...

 hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION